Ridgetop Health is a mid to late stage private equity platform focused on life science companies, with strong emphasis on digital health, early disease detection diagnostics, and technologies that enable precision medicine.
We invest in exceptional people with innovative ideas relentlessly focused on bringing their vision to life and building great companies in the process.
Within life sciences and the selected sub disciplines mentioned above, Ridgetop Health likes to select early growth companies (less than $150 million valuation) that are based on innovative ideas /technologies with a clear and scalable business model. Portfolio companies must have validation data to support the application of their technology as well as experienced teams with strong drive and the capital discipline to build a long-term successful company.
Ridgetop Health differs from other funds in that, not only do we invest in our portfolio companies ourselves, but we also bring our strategic and operational expertise to the table to advise and support the management of our portfolio investments and to accelerate their growth plans.
We are currently reviewing investment opportunities for both Click Therapeutics and VisionGate and preparing to launch our next discretionary fund later this year.
Ridgetop Health invests in exceptional people with innovative ideas relentlessly focusing on building great companies.
We advise and support management teams to accelerate their growth plans.
Ridgetop Health brings our strategic and operational expertise to guide our portfolio companies as well as other companies of interest to us that may become future 'to-be' portfolio companies.
Maria has a 20-year history in healthcare working alongside companies of all sizes and assisting them across an entire spectrum of functions, including: Strategic Planning, Financing, Business Development, Partnership Management, Sales and Marketing, and Capital Raising. Maria is originally a human geneticist by training turned accountant, investment banker, and pharmaceutical executive. She has extensive international operational experience across different continents.
For the last two years, Maria has been the founder and manager of Aelius Healthcare Innovations Fund prior to moving its platform to Ridgetop Capital. Maria is actively involved in advising her portfolio companies and travels regularly between her offices in Pittsburgh, NYC, and Miami.
Maria spent the last 10 years working in the Pharmaceutical Industry at Novartis in senior roles. She is the former Head of Sales & Marketing for Sandoz Latin America and former CEO/GM of Spain & Portugal at Novartis Vaccines & Diagnostics. Prior to this, Maria spent seven years in investment banking as former Vice President of Global Healthcare Marketing and Sales at Morgan Stanley, London. She trained as a certified accountant and audit manager at PricewaterhouseCoopers, London. She holds an MPH from Columbia University, New York and a BSc in Human Genetics, from the University College London.